Acumen Pharmaceuticals, Inc. Financial and Nonfinancial Liabilities, Fair Value Disclosure
Acumen Pharmaceuticals, Inc. (ABOS) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $1.13 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-12
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $1.13M.
- 2026-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $970.00K.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $1.43M.
- 2025-09-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $1.26M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $970.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.43M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $820.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $780.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $970.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.52M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.51M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.61M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.56M 10-K · filed 2025-03-27 |
| 2020-12-31 | $5.41M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |